Cancer Immunotherapy Focus

May 2016


IDO1 inhibitors – reversible or irreversible?

IDO1 and TDO are overexpressed and/or overactive in many tumours, resulting in Tryptophan catabolism, starvation, and cell cycle arrest and death of effector T cells within the tumour microenvironment. To define the mechanism of action of IDO1 inhibitors, BPS Bioscience have recently released the IDO1 Inhibitor Mechanism of Action Assay Kit, which comes with all reagents necessary to run the assay including a Reversible and an Irreversible Reference Inhibitor.

Learn more about this innovative kit


Screen for inhibitors of PD-1 signaling

Therapeutic manipulation of immunopathways has led to promising clinical results for the treatment of a number of diseases, with the first therapeutic antibodies now brought to the market and approved for treatment of diverse cancer types. In this post, our specialist reviews a versatile tool to screen for activators or inhibitors of PD-1 signaling, or characterize biological activity of PD-1, and its interaction with ligands.

Run cell-based inhibitor screenings on PD-1/PD-L1/PD-L2 binding

Mutant PD-L1 proteins for antibody epitope mapping

Knowledge about which epitopes are recognized by a blocking antibody can help researchers to develop improved antibodies for drug discovery and to better understand the mechanism of inhibition. The first therapeutic antibodies in this field have been directed against the checkpoint receptor PD-1.

In this post, Ali, our specialist invites you to look at 14 PD-L1 proteins with point mutations, enabling scientists to conduct epitope mappings of their antibodies raised again PD-L1.

Discover these tools perfect for your epitope mapping studies

Co-culture PD-L1 and TCR effector & target cells 

BPS Bioscience have just released a new kit allowing researchers to generate a PD-L1 and TCR activator over-expressing target cell line.  
The TCR Activator / PD-L1 Mammalian Expression Kit comes with an expression vector constitutively expressing TCR activator and human PD-L1, and a control vector expressing TCR activator alone.

Generate your PD-L1 & TCR activator over-expressing target cell line


Toxicity Assessment of Co-Culture Human Systems 

Many chemotherapeutic drugs require bioactivation before they reach full potency.  

This bioactivation is accomplished through many different mechanisms, but frequently in the liver before the drug enters circulation. Inadequacy of animal models to predict human biology in the drug development process is becoming increasingly clear due to species differences in uptake and metabolism at both the cellular and organ levels. 

Feasibility of creating a multi-organ system capable of testing the ability of a human liver cell line to activate a panel of chemotherapeutic drugs has recently been demonstrated... [ Read more ]


Find the best epigenetic enzyme substrates 

There is a large number of high quality native, recombinant nucleosomes, histones & histone polymers, peptide substrates etc. available to researchers. You can even choose to go for Designer Nucleosomes (dNuc), such as recently launched by EpiCypher.

Which substrates are the best for your research? Are all Designer Nucleosomes of equal quality?

Browse this article by our specialist Ali el Bayâ, and download your copy of the white paper to read the Tale of Two Cysteines... [ Read more ]


2016 Microtubule Symposium - 29/05 to 01/06

The 2016 Microtubule Symposium (Heidelberg, Germany) coincides with the 50th anniversary of the discovery of tubulin. Researchers from the main domains of the Microtubule field will have many opportunities for interaction and collaboration, to advance the understanding of the microtubule cytoskeleton in health and disease.

Meet Christian Gadomsky from tebu-bio there!

Our Quality Promise to you!
Get to work with peace of mind...
Find your reagents and services with our  powerful search engine, order online, contact our specialists with our Live Chat...
tebu-bio's newsletters cover many of your favourite research themes...
Subscribe now!